Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice
Author:
Publisher
Elsevier BV
Subject
Anesthesiology and Pain Medicine,Rheumatology
Reference36 articles.
1. CT-P13: design, development, and place in therapy;Gabbani;Drug Des Devel Ther,2017
2. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the planetra study;Yoo;Ann Rheum Dis,2013
3. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group Planetas study;Park;Arthritis Res Ther,2016
4. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France;Avouac;Semin Arthritis Rheum,2018
5. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care;Glintborg;Scand J Rheumatol,2018
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-25
2. Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study;GastroHep;2023-08-25
3. Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database;BioDrugs;2023-06-06
4. Switching between Originators and Biosimilars in Dermatology: A Systematic Review of Real-World Clinical Studies;Biologics;2023-04-27
5. Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort;United European Gastroenterology Journal;2023-02-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3